Neoadjuvant Pembrolizumab, PD-1 Inhibitor, Combo with Chemo Met Co-Primary Endpoint of Pathological Complete Response (pCR) in Phase 3 KEYNOTE-522 Trial in Triple-Negative Breast Cancer, Regardless of PD-L1 status. Full results at upcoming meeting. #bcsm